ALX-0171: Phase I data

An open-label, German Phase I trial in 24 adults with hyper-reactive airways showed that single ascending-doses of 2-200 mg ALX-0171 and once-daily 140 and 200 mg inhaled ALX-0171 for 5 days were well...